Prime Medicine appoints Jeff Marrazzo to board of directors

Prime Medicine, Inc.

Jeff Marrazzo appointed as Class II director effective May 10, 2023, until 2024 annual meeting.
Granted stock options for 92,000 shares vesting in three equal annual installments.
Annual cash compensation of $40,000 for board service and $6,000 for Compensation Committee.
Also appointed to the Compensation Committee.
No arrangements or transactions requiring disclosure under Item 404(a).

item 5.02

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

Jeff Marrazzo

Director

PRME · Prime Medicine, Inc.

Effective: 2023-05-10
Filed: May 11, 2023, 7:59 PM ET

On May 10, 2023, the Board of Directors (the “Board”) of Prime Medicine, Inc. (the “Company”) appointed Jeff Marrazzo as a director of the Company.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Jeff Marrazzo was appointed as Director at Prime Medicine, Inc..

Action: appointed
Role: Director

Exact text from the filing

On May 10, 2023, the Board of Directors (the “Board”) of Prime Medicine, Inc. (the “Company”) appointed Jeff Marrazzo as a director of the Company.

View on SEC.gov

Prime Medicine, Inc. filing history →

Source: SEC EDGAR

accession 0001628280-23-017420

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.